Company intelligence / Profile preview
Beijing SyngenTech Co., Ltd.
Beijing（北京）, Beijing Municipality（北京市）, 中国（China）syngentech.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company’s lead candidate, SynOV1.1 targeting CSF‑2R in advanced malignant solid neoplasms, has reached Phase 1 clinical trials. Other programs are in preclinical stages or have been discontinued. No published clinical results yet[7].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virusesCircular RNA-based therapeuticsNucleic acid drugs[4][7]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Beijing SyngenTech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing SyngenTech Co., Ltd..